Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 1, 2011, Pages 29-38

  Yoshida, Jin ^a   Koda, Shigeki ^b   Nishida, Shozo ^c   Yoshida, Toshiaki ^a   Miyajima, Keiko ^a   Kumagai, Shinji ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

air and surface contamination; Antineoplastic drugs; biological monitoring; occupational exposure

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; PLATINUM DERIVATIVE;

AIR CONDITIONING; ARTICLE; HOSPITAL; INDOOR AIR POLLUTION; JAPAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; WORK ENVIRONMENT;

ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; HOSPITALS; HUMANS; JAPAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PHARMACISTS;

EID: 79952409427     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155210380485     Document Type: Article

References (30)

1. Connor TH and McDiarmid MA Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006 ; 56: 354-365. (Pubitemid 44903909)
2. Tomioka K. and Kumagai S. Health risks of occupational exposure to anticancer (antineoplastic) drugs in health care workers. Sangyo Eiseigaku Zasshi 2005 ; 47: 195-203.
3. Shirato S. Problems of cytotoxicity drug mainly based on antineoplastic tumor medicine. J Jpn Med Waste Res 1992 ; 5: 1-32.
4. National Institute for Occupational Safety and Health (NIOSH). NIOSH ALERT preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. Cincinnati, USA: NIOSH, 2004.
5. International Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007 ; 13: 1-81.
6. Society of Hospital Pharmacists of Australia. Guidelines of safe handling of cytotoxic drugs in pharmacy departments and hospital wards. Hospital Pharm 1981 ; 16: 17-20.
7. Canadian Society of Hospital Pharmacists. Guidelines for the handling of hazardous pharmaceuticals. Can J Hosp Pharm 1981 ; 34: 126-128.
8. Health and Safety Executive (UK). Precautions for the safe handling of cytotoxic drugs. Guidance Note MS 21, 1984.
9. Yodaiken RE and Bennett D. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am J Hosp Pham 1986 ; 43: 1193-1204.
10. Kitada M., Morikawa A., Katou H., et al. The revised version of guideline of handling antineoplastic drugs in medical center - Manual of handling antineoplastic drugs. Tokyo, Japan: Jiho Co., 2005.
11. Nabeshima T., Sugiura S., Nakanishi H., et al. Guideline for aseptic handling of injection and antineoplastic drugs. Tokyo, Japan: Yakuji Nippo Co., 2008.
12. Yoshida J., Kosaka H., Nishida S., et al. Actual conditions of the mixing of antineoplastic drugs for injection in hospitals in Osaka Prefecture, Japan. J Occup Health 2008 ; 50: 86-91. (Pubitemid 351680014)
13. Yoshida J., Kosaka H., Tomioka K., et al. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J Occup Health 2006 ; 48: 517-522. (Pubitemid 46057884)
14. Sasaki M., Dakeishi M., Hoshi S., et al. Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay. J Occup Health 2008 ; 50: 7-12. (Pubitemid 351680002)
15. Yoshida J., Tei G., Mochizuki C., et al. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg 2009 ; 53: 153-160.
16. Sessink PJ and Ryden N. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm 1999 ; 34: 1311-1317. (Pubitemid 30154728)
17. Vandenbroucke J. and Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract 2001 ; 6: 146-152.
18. Connor TH, Anderson RW, Sessink PJ, et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm 2002 ; 59: 68-72. (Pubitemid 34415055)
19. Nygren O., Gustavsson B., Ström L., et al. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit 2002 ; 4: 739-742. (Pubitemid 35221766)
20. Spivey S. and Connor TH Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharma 2003 ; 38: 135-139. (Pubitemid 36232308)
21. Wick C., Slawson MH, Jorgenson JA, et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agent. Am J Hosp Pharm 2003 ; 60: 2314-2320. (Pubitemid 44712872)
22. Harrison BR, Peters BG and Bing MR Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm 2006 ; 63: 1736-1744. (Pubitemid 44413510)
23. Sessink PJ, Boer KA, Scheefhals AP, et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992 ; 64: 105-112.
24. Sessink PJ, Scholtes MM, Anzion RB, et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr 1993 ; 616: 333-337. (Pubitemid 23196163)
25. Connor TH, Shults M. and Fraser MP Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37 degrees C using a desiccator technique. Mutat Res 2000 ; 470: 85-92.
26. Mochizuki C., Fujikawa I., Tei G., et al. A comparison of cleaning solutions in the biological safety cabinet for preparation of anti-cancer agents. J Jpn Soc Hosp Pharm 2008 ; 44: 601-604.
27. Massoomi FF, Neff B., Pick A., et al. Implementation of a safety program for handling hazardous drugs in a community hospital. Am J Health Syst Pharm 2008 ; 65: 861-865.
28. Hedmer M., Tinnerberg H., Axmon A., et al. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008 ; 81: 899-911.
29. Connor TH, Anderson RW, Sessink PJ, et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999 ; 56: 1427-1432. (Pubitemid 29331357)
30. Sessink PJ, Anzion RB, Van den Broek PH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992 ; 14: 16-22.